Tomasz P. Stompór

机构：University of Warmia and Mazury in Olsztyn · ORCID：0000-0002-3944-0850

发表论文 228 篇 · 总被引 3568 次 · h-index 30

代表论文

• Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial (2023 · The Lancet · 被引 302)
• Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial (2023 · The Lancet · 被引 226)
• Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy (2022 · Kidney International · 被引 225)
• Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis (2022 · Diabetes Care · 被引 215)
• Inflammation and Oxidative Stress in Diabetic Kidney Disease: The Targets for SGLT2 Inhibitors and GLP-1 Receptor Agonists (2021 · International Journal of Molecular Sciences · 被引 195)
• Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes (2023 · Annals of Internal Medicine · 被引 102)